U.S. markets close in 1 minute

  • S&P 500

    3,856.98
    +5.13 (+0.13%)
     

  • Dow 30

    31,224.46
    +36.08 (+0.12%)
     

  • Nasdaq

    13,533.73
    +76.48 (+0.57%)
     

  • Russell 2000

    2,147.80
    -12.82 (-0.59%)
     

  • Crude Oil

    53.05
    -0.26 (-0.49%)
     

  • Gold

    1,869.50
    +3.00 (+0.16%)
     

  • Silver

    26.03
    +0.26 (+1.02%)
     

  • EUR/USD

    1.2173
    +0.0058 (+0.47%)
     

  • 10-Yr Bond

    1.1090
    +0.0190 (+1.74%)
     

  • GBP/USD

    1.3738
    +0.0083 (+0.60%)
     

  • USD/JPY

    103.4920
    -0.0780 (-0.08%)
     

  • BTC-USD

    32,176.35
    -2,775.33 (-7.94%)
     

  • CMC Crypto 200

    638.17
    -41.74 (-6.14%)
     

  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     

  • Nikkei 225

    28,756.86
    +233.60 (+0.82%)
     

Internet of Things (IoT) Market Review 2012-2019 and Forecast 2020-2027 (COVID-19 Adjusted)

·5 min read

DUBLIN, May 29, 2020 /PRNewswire/ -- The "Internet of Things (IoT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

Amid the COVID-19 crisis and the looming economic recession, the Internet of Things (IoT) market worldwide will grow by a projected US$876.5 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 31.4%.

Applications & Analytics, one of the segments analyzed and sized in this study, is forecast to grow at over 37.8% and reach a market size of US$466.4 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Applications & Analytics market will be reset to a new normal which going forward in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 34.6% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$22.5 Billion to the region's size over the next 7 to 8 years. In addition, over US$41.3 Billion worth of projected demand in the region will come from Rest of the European markets. In Japan, the Applications & Analytics segment will reach a market size of US$21.1 Billion by the close of the analysis period.

Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Internet of Things (IoT) market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 30.1% over the next couple of years and add approximately US$85.1 Billion in terms of addressable market opportunity.

Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Internet of Things (IoT) market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Key Topics Covered

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Impact of COVID-19 and a Looming Global Recession

  • What is IoT?: A Review of this Intriguing Technology Built for Disruption

  • Recent Market Activity

  • Market Outlook

  • Global Competitor Market Shares

  • Internet of Things (IoT) Competitor Market Share Scenario Worldwide (in %): 2020 & 2029

2. FOCUS ON SELECT PLAYERS

IoT Security Solution Providers

  • Bitdefender (Romania)

  • DigiCert (USA)

  • Gemalto N.V. (Netherlands)

  • Karamba Security (USA)

  • Symantec Corporation (USA)

  • Trustwave Holdings, Inc. (USA)

  • Verizon Enterprise Solutions (USA)

IoT Cloud Service Providers

  • Amazon Web Services (USA)

  • Google, Inc. (USA)

  • Microsoft Corporation (USA)

  • General Electric Company (USA)

  • Salesforce.com, Inc. (USA)

  • Telit Communications PLC (UK)

  • Zebra Technologies Corporation (USA)

IoT Sensor Manufacturers

  • ARM Ltd. (UK)

  • Bosch Software Innovations GmbH (Germany)

  • Honeywell International, Inc. (USA)

  • Infineon Technologies AG (Germany)

  • InvenSense Inc. (USA)

  • IBM Corporation (USA)

  • STMicroelectronics N.V. (Switzerland)

IoT Semiconductors/IoT Chips

  • Atmel Corporation (USA)

  • Freescale Semiconductor, Inc. (USA)

  • Intel Corporation (USA)

  • Qualcomm Technologies, Inc. (USA)

  • Texas Instruments (USA)

IoT Network Providers

  • AT&T, Inc. (USA)

  • Telefnica S.A. (Spain)

  • Vodafone Group PLC (UK)

  • Verizon Communications, Inc. (USA)

Other IoT Solution Providers

  • Ayla Networks (USA)

  • B-Scada (USA)

  • CLX Communications (Sweden)

  • ErgoTech Systems (USA)

  • Fujitsu Limited (Japan)

  • Greenwave Systems (USA)

  • Ingenu Inc. (USA)

  • Silver Spring Networks (USA)

  • Samsung Electronics Co. Ltd. (South Korea)

  • SAP SE (Germany)

3. MARKET TRENDS & DRIVERS

  • IoT: A Transformational Force to Reckon with in the Modern Connected World

  • Gradual Categorical Realization of Promised Benefits Drives VC Interest in IoT

  • A Peek into the Massive Potential and True Scale of IoT Opportunity

  • Falling Sensor Costs Drive Proliferation of IoT

  • Developments in Big Data Analytics Play an Instrumental Role in Driving Real World Commercial Benefits and Thereby Success of IoT

  • Prescriptive Analytics Emerges as the Most Potent Big Data Tool to Drive Value of IoT Implementations

  • Omnipresence of Smartphones, Tablets & Declining Price of Connected Devices Rank as One of the Major Factors Driving Adoption of IoT

  • Developments in Internet and Broadband Technologies Provide the Foundation for the IoT Ecosystem

  • Growing Investments in 4G/LTE & 5G to Strengthen the Robustness of Cellular IoT Especially in LPWAN Applications

  • Rise of Wireless Short-Range Networking Technologies to Benefit Penetration of Low Resource IoT Devices

  • Wi-Fi Promises to Emerge as a Ubiquitous Connectivity Solution for both Short and Long Range IoT Applications

  • Many Flavors of Bluetooth Widens the Technology's Role in IoT

  • Especially Designed for Device-to-Device Communication, ZigBee Promises to Unify IoT

  • Z-Wave: The Most interoperable Technology Developed for Smart Home Applications

  • Open-Source Thread Networking Protocol Intensifies Competition for IoT Standards

  • Built-in AES128 Encryption Makes 6LoWPAN a Popular Low-Power IoT Wireless Network Solution

  • Other Noteworthy Technologies that Enable Easy Creation of Smart Environment

  • Blockchain to Revolutionize IoT Security & Accelerate Mainstream Adoption of IoT

  • Security Issues: The Cog in the Wheel Impeding IoT Development & Proliferation

  • Blockchain Holds the Answers to Current IoT Security Issues

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 114

For more information about this report visit https://www.researchandmarkets.com/r/2o60za

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/internet-of-things-iot-market-review-2012-2019-and-forecast-2020-2027-covid-19-adjusted-301067745.html

SOURCE Research and Markets

Latest Stories

  • Powerball winner in Maryland should remember this before cashing the $730 million ticket: expert

    Be wise with how you allocate your money, $730 million Powerball winner.

  • Jim Cramer: Here Are the Biden Stocks

    As power has changed hands in the White House, we can expect these names -- and themes -- to benefit.

  • David Einhorn — Notorious Tesla Short Seller — Just Had His Best Quarter Ever

    Greenlight Capital hedge fund manager and notorious value investor David Einhorn just released his annual letter to investors, which revealed a record quarter for Einhorn to close out a difficult 2020.Finishing Strong: Greenlight took a massive hit from a large short position in Tesla Inc (NASDAQ: TSLA) in 2020, but Greenlight finished strong with a 25% gain in the fourth quarter. Despite the disastrous Tesla short position, Einhorn was able to salvage a 5.2% overall gain for the fund for the year.The Greenlight letter disclosed several new long positions heading into 2021, including Fubotv Inc (NYSE: FUBO), Danimer Scientific Inc (NYSE: DNMR) and Neubase Therapeutics Inc (NYSE: NBSE), according to Bloomberg. All three stocks were trading higher by more than 10% on Thursday.Einhorn said the Tesla short position was Greenlight's biggest loser in 2020, although he reportedly adjusted the position prior to Tesla's inclusion in the S&P 500.Related Link: Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their PortfoliosEinhorn's Recent Struggles: Greenlight has significantly underperformed the S&P 500 in recent years as growth stocks have soared and value stocks have lagged. Greenlight reported a 14% net gain in 2019 following a 38% net loss in 2018, its worst year since the fund's inception in 1996.Einhorn gained mainstream notoriety on Wall Street back in 2007 when he disclosed a short position in Lehman Brothers prior to the bank's collapse in 2008. However, he had drawn a lot of criticism in recent years for his persistent short position in Tesla and his often heated public communications with Tesla CEO Elon Musk."TSLA cars are not a fad; if they were, TSLA would sell many more than it does. The fad is in owning TSLA stock," Einhorn said in the letter.As of the end of the third quarter, Greenlight's three largest long positions were Green Brick Partners Inc (NYSE: GRBK), Brighthouse Financial Inc (NASDAQ: BHF) and Atlas Air Worldwide Holdings, Inc. (NASDAQ: AAWW).Benzinga's Take: Economist John Maynard Keynes famously said "the market can stay irrational longer than you can stay solvent," and Einhorn's performance in recent years highlight just how much of a toll a single short position can take on an entire portfolio when the stock in question gets caught in a potential market bubble. Short positions can result in unlimited theoretical losses, whereas standard long positions are capped at just 100% downside.Image credit: PokerListings, YouTubeSee more from Benzinga * Click here for options trades from Benzinga * Why This Enphase Energy Analyst Is Bullish Following Tesla-Driven Sell-Off * Here's How Americans Are Spending Their Stimulus Payments(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Biden Boom Is Coming And These Stocks Could Soar

    With the Biden Administration likely to pump trillions into green energy infrastructure in the coming years, renewable stocks should outperform the market

  • If I inherit a Roth IRA, are the distributions taxed?

    Q: When the inheritor of a Roth IRA receives the funds, is it true that the distributions would not be taxed? It would be unusual for any taxes to be due on an RMD from an inherited Roth IRA. The only portion of an inherited IRA that could be subject to tax is earnings.

  • Column: What happens to businesses when their CEOs become extremists?

    My Pillow CEO Mike Lindell is the latest business leader to discover the downside of becoming a crank.

  • BlackRock raises dividend by 14%, with first new payout in March

    BlackRock Inc. said Thursday that it will raise its dividend by 14%. The investment management's new quarterly dividend of $4.13 a share, up from $3.63 a share, will be payable March 23 to shareholders of record on March 5. The stock slipped 0.1% in afternoon trading. At current prices, the new annual dividend rate implies a dividend yield of 2.23%, compared with the dividend yield for the SPDR Financial Select Sector ETF of 1.95% and the implied yield for the S&P 500 of 1.48%, according to FactSet. BlackRock's stock has gained 16.7% over the past three months, while the financial ETF has rallied 24.1% and the S&P 500 has advanced 12.1%.

  • Your next stimulus check — for $1,400 — is about to start moving closer

    Congressional leaders plan to get "right to work" on it. How soon might you get the cash?

  • The Bull Case for FuboTV and More on the Market From David Einhorn’s Greenlight Capital

    Stock in the streaming provider jumped after the hedge fund disclosed it had been a pre-IPO investor.

  • How Is Your 401(k) Taxed When You Retire?

    The taxes you owe on your 401(k) distributions at retirement depend in large part on whether your funds are in a traditional 401(k) or a Roth 401(k).

  • 2 “Strong Buy” Penny Stocks That Could See Outsized Gains

    Well, it’s official. Joe Biden is now President, and he’ll be backed – at least for the short term – by Democratic majorities in both Houses of Congress. Wall Street is taking the measure of the new Administration, and sees, among its first moves, a boost in fiscal stimulus that is likely to goose consumer spending, bump corporate profits, and provide general economic support in the first half of 2021. Covering the situation for Goldman Sachs is investment strategist David Kostin, who is bullish on the near-term prospects for fiscal stimulus. In light of it, Kostin sets the Goldman outlook for this year at 6.4% GDP growth; he sees continued high growth next year, and sets the 2022 prediction at 4%. These outlook numbers are up from the previously published 5.9% and 3.7%. To this end, Kostin sees S&P 500 reaching 4,300 by year’s end, which would be a gain of 12% from current levels. “Elections have consequences. Democratic control of Washington, D.C. after January 20 will bring greater fiscal spending, faster GDP growth, more inflation, and higher interest rates than we had previously assumed,” Kostin noted. With markets looking up, investors are looking for the stocks that are ready for gains. Penny stocks, equities priced at less than $5 per share, are a natural place to search for potential winners. Their low price means that even a small incremental gain will translate into large percentages. However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts. Taking the risk into consideration, we used TipRanks’ database to find compelling penny stocks with bargain price tags. The platform steered us towards two tickers sporting share prices under $5 and “Strong Buy” consensus ratings from the analyst community. Not to mention substantial upside potential is on the table. AzurRx BioPharma (AZRX) We’ll start with a company specializing in gastrointestinal disease, AzurRx. This company is focused on creating non-systemic, targeted recombinant therapies for GI ailments. AzurRx has a pipeline of three drug candidates, at several levels of the development process. The key pipeline candidate, MS1819, is being investigated as a treatment for exocrine pancreatic insufficiency for patients also suffering from cystic fibrosis. MS1819 is a recombinant lipase, derived from a yeast strain. The drug is designed to target fat molecules in the digestive tract, allowing patients to absorb the broken-down fats for nutritive value. The drug is currently in Phase 2 trials, which are scheduled for completion in the first half of this year. As of January 21, the first two patients in the Phase 2b OPTION 2 extension study have been dosed with the treatment, and the Data Monitoring Committee (DMC) “remains supportive of the program.” In another important development, AzurRx announced earlier this month that it is entering a partnership with First Wave Bio to study oral and rectal formulation of Niclosamide to treat immune checkpoint inhibitor-associated colitis (ICI-AC) and COVID-19 related gastrointestinal infections. The estimated market for Niclosamide as a treatment for COVID-related GI problems exceeds $450 million. Based on multiple potentially significant clinical catalysts as well as its $0.98 share price, several members of the Street think that now is the right time to pull the trigger. Jonathan Aschoff, of Roth Capital, is bullish on AzurRx, basing his longer-term forecasts on the probable success of MS1819. “We base our valuation for AZRX on projected future U.S. sales from MS1819 for the treatment of EPI due to CF and CP, using an initial annual price of about $18,000, a price that is consistent with currently available PERTs. We project MS1819 to be commercialized in the U.S. in 2023, generating sales of $272 million in 2030. Ex-U.S. commercial success for MS1819, or commercial success from the early-stage beta-lactamase program would provide upside to our valuation,” Aschoff noted. The analyst also looks forward to initial clinical results of Niclosamide in COVID-19 GI infection and in ICI-AC potentially, noting: "Niclosamide was FDA approved in 1982 to treat intestinal tapeworm infections and is on the World Health Organization’s list of essential medicines. Given the millions of patients that have taken the drug, the safety profile has largely been established, thereby lowering developmental risk.” Given all of the above, Aschoff rates AZRX as a Buy, and his $7 price target suggests a sky-high 608% upside for the year ahead. (To watch Aschoff’s track record, click here) Overall, the analyst consensus on AZRX shares is a Strong Buy; the stock has 4 recent reviews, including 3 Buys and a single Hold. In addition, the $4 average price target brings the upside potential to 304%. (See AZRX stock analysis on TipRanks) ProQR (PRQR) ProQR is a biotechnology company focused on treatments for congenital progressive blindness. Specifically, the firm is working on medications to reverse a group of genetic sight disorders called inherited retinal diseases. These diseases currently have no effective treatments. The company has a research pipeline of five drug candidates, in varying stages of the research process. The two that are farthest along are QR-110 (Sepofarsen), and QR-421. Of those two, QR-110 is currently in Phase 2/3 studies. This candidate is an RNA therapy designed to correct the most common CEP290 gene mutation causing Leber congenital amaurosis 10 (LCA10). This is a severe genetic retinal disease that affects as many as 3 in 100,000 children. QR-421 is another RNA therapy, this one focused on exon 13 mutations in the USH2A gene. These mutations cause blindness due to retinitis pigmentosa and/or Usher syndrome. QR-421 is in Phase 1/2 studies, with an aim of restoring lost vision or preventing the loss in the first place. Covering the stock for JMP, analyst Jonathan Wolleben points to Sepofarsen as a key component of his bullish thesis. “We continue to feel good about sepofarsen’s chance of success in Illuminate for multiple reasons: 1) Phase 1/2 confirmed the target registrational dose and dosing interval (6 months); 2) patients had clinically significant and durable BCVA improvements after 12 months – pivotal primary endpoint; 3) supportive secondary efficacy measures (FST, mobility); 4) similar responses seen in second treated eyes; 5) long-term safety confirms positive risk/benefit; and 6) Illuminate patient population was enriched based on Phase 1/2 results (baselinevision of >/=hand motion). We assign sepofarsen a 60% POS and model LCA10 as an ~$300M opportunity to PRQR at peak penetration," Wolleben opined. In line with his upbeat outlook, Wolleben puts a $20 price target on the stock, implying a 384% one-year upside, along with an Outperform (i.e. Buy) rating. (To watch Wolleben’s track record, click here) All in all, PRQR gets a unanimous Strong Buy rating from the analyst consensus, based on 3 positive stock reviews. Shares are currently trading for $4.13, and their $20.67 average price target is slightly more bullish than Wolleben’s, suggesting an upside of 400% for the coming 12 months. (See PRQR stock analysis at TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Tesla isn't the only auto stock exploding right now

    Other auto stocks joins in the impressive rally in Tesla's stock. Here's why.

  • Big U.S. oil drillers have federal permits to mute effect of any Biden ban

    U.S. President Joe Biden's promised ban on new oil and gas drilling on federal lands would take years to shut off production from top shale drillers because they already have stockpiled permits, according to Reuters interviews with executives. But smaller independent oil drillers without the resources of big corporations were more worried about Biden's vow to toughen regulations and stop issuing new permits on federal lands, part of his sweeping plan to combat climate change and bring the economy to net zero emissions by 2050. Federal lands are the source of about 10% of U.S. oil and gas supply.

  • Dow Jones Hits Record High As Apple Jumps; Hot IPO Stock Airbnb Triggers Key Sell Rule

    The Dow Jones Industrial Average hit record highs Thursday, as Apple stock jumped near a new buy point. Hot IPO stocks Airbnb and DoorDash slid.

  • GE Earnings: What to Look For From GE

    GE reports Q4 earnings before market open on January 26. Can it boost revenue in its renewable energy unit and reverse a string of earnings declines?

  • Stock Market Today With Jim Cramer: Buy Plug Power

    Jim Cramer discusses the latest stock market news including Amazon's plan to help with vaccines, FuelCell's earnings and markets on Thursday.

  • Dow Jones, Nasdaq Hit New Highs; These Stocks Flash Buy Signals

    The Dow Jones Industrial Average advanced modestly in today's stock market, while the S&P 500 and Nasdaq once again continued to hit new highs.

  • Is Boeing Stock A Buy Ahead Of Earnings With 737 Max Back In Service?

    Is Boeing stock a good buy now as the 737 Max grounding is lifted? Look at the aerospace giant's fundamentals and stock chart.

  • PayPal Stock Looks Like a Cryptocurrency Winner. It Might Be Bad News for Visa and Mastercard.

    How much could Bitcoin be worth to PayPal Holdings? A lot more than what is now priced into the stock.

  • Jim Cramer Discusses Procter & Gamble, Intel And Cautions On SPACs

    Jim Cramer shared his first thoughts on the market Thursday discussing recent earnings and the large number of SPACs.On Procter and Gamble: The recent earnings report from Procter & Gamble Co (NYSE: PG) is being undervalued by investors, Cramer said.Procter & Gamble beat earnings per share estimates with a second quarter total of $1.64. Revenue of $19.75 billion beat the estimate of $19.27 billion."I thought Procter & Gamble was great," Cramer said. The long-term projections for Procter & Gamble look good with mid-single-digit growth, he added.Investors can add Procter & Gamble to help build a diversified portfolio."People are yawning at it," Cramer said, noting investors would rather own GameStop Corp (NYSE: GME) or SPACs.Related Link: PreMarket Prep Stock Of The Day: Procter & GambleOn SPACs: The CNBC host added some cautionary tales for SPACs. While there are some good SPACs, there are too many on the market and some could be bringing bad companies public."Good money bringing down the rest," Cramer said.The SPAC process allows companies the chance to hype something for three weeks and get their share price higher.Cramer questioned the companies that are launching more than one SPAC at a time and if they can truly commit their time and dedication to all the ventures they're in.On Intel: Shares of Intel Corp (NASDAQ: INTC) have risen over the last month with news that it's changing to a new CEO."Intel is pretty static," Cramer said.He hopes a new CEO can turnaround as they've lost their way compared to rivals like Advanced Micro Devices (NASDAQ: AMD) and NVIDIA Corp (NASDAQ: NVDA): "Intel is full of sound and fury, signaling nothing."See more from Benzinga * Click here for options trades from Benzinga * 5 Things You Might Not Know About Kamala Harris * 7 SPACs To Play The Rise Of Bitcoin, Cryptocurrency Stocks(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.